Abstract
High-Dose Therapy for High-Risk, Aggressive Lymphoma The role of autologous stem-cell transplantation (ASCT) as consolidation treatment for higher-risk, aggressive B- and T-cell non-Hodgkin lymphomas (NHLs) remains controversial. In the phase III, randomized, SWOG S9704 trial, U.S. and Canadian researchers compared the use of 8 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) with or without rituximab versus CHOP for 6 cycles followed by ASCT in patients who achieved partial or complete remission after 5 cycles. Eligible patients were aged <65 with B- or T-cell diffuse aggressive NHL and high-intermediate or high-risk, age-adjusted International Prognostic Index (IPI) scores. Patients with high-intermediate IPI scores experienced no difference with ASCT versus chemotherapy only in terms of 2-year progression-free survival (PFS; 66% vs. 63%) or overall survival (OS; 70% vs. 75%), whereas those with high-risk IPI …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
